Item 5.07 Submission of Matters to a Vote of Security Holders. Annual Meeting of Stockholders

Item 8.01 Other Events. On June 4, 2026, the Company received marketing authorization from the Therapeutic Goods Administration of Australia for Amtagvi® for previously treated advanced (metastatic or unresectable) melanoma. The full text of the press release announcing the approval is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. 99.1 Press Release of Iovance Biotherapeutics, Inc., dated June 3, 2026. ──────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded as Inline XBRL document) SIGNATURES